share_log

Elevai Labs | 8-K: Current report

Elevai Labs | 8-K: Current report

Elevai Labs | 8-K:重大事件
美股SEC公告 ·  2024/11/14 00:25

Moomoo AI 已提取核心信息

Elevai Labs has received a conditional extension from Nasdaq to maintain its listing, following its failure to meet the minimum $1.00 bid price requirement since March 6, 2024. The company must complete a reverse stock split by December 26, 2024, and demonstrate compliance with the bid price rule by January 9, 2025.The company's compliance plan, presented at the October 22 Nasdaq hearing, includes raising $8 million through a public offering, obtaining shareholder approval for a reverse stock split, and completing a tender offer to exchange common stock for non-trading preferred stock by December 16, 2024.During the extension period until January 9, 2025, Elevai Labs must promptly notify Nasdaq of any significant events affecting its compliance status. The company has until November 22, 2024, to request a review of the Panel's determination by the Nasdaq Listing and Hearing Review Council, which would require a $15,000 review fee.
Elevai Labs has received a conditional extension from Nasdaq to maintain its listing, following its failure to meet the minimum $1.00 bid price requirement since March 6, 2024. The company must complete a reverse stock split by December 26, 2024, and demonstrate compliance with the bid price rule by January 9, 2025.The company's compliance plan, presented at the October 22 Nasdaq hearing, includes raising $8 million through a public offering, obtaining shareholder approval for a reverse stock split, and completing a tender offer to exchange common stock for non-trading preferred stock by December 16, 2024.During the extension period until January 9, 2025, Elevai Labs must promptly notify Nasdaq of any significant events affecting its compliance status. The company has until November 22, 2024, to request a review of the Panel's determination by the Nasdaq Listing and Hearing Review Council, which would require a $15,000 review fee.
Elevai Labs已收到纳斯达克的有条件延期,以维持其上市资格,因为自2024年3月6日起未能满足最低1.00美元买盘价格要求。该公司必须在2024年12月26日之前完成反向股票拆分,并在2025年1月9日之前证明符合买盘价格规则。该公司在10月22日的纳斯达克听证会上提出的合规计划包括通过公开发行筹集800万美元,获得股东批准进行反向股票拆分,并在2024年12月16日之前完成一次要约收购,以将普通股换为非交易优先股。在截至2025年1月9日的延期期间,Elevai Labs必须及时通知纳斯达克任何影响其合规状态的重大事件。该公司必须在2024年11月22日之前请求纳斯达克上市和听证审查委员会对小组的决定进行审查,这将需要支付15,000美元的审查费用。
Elevai Labs已收到纳斯达克的有条件延期,以维持其上市资格,因为自2024年3月6日起未能满足最低1.00美元买盘价格要求。该公司必须在2024年12月26日之前完成反向股票拆分,并在2025年1月9日之前证明符合买盘价格规则。该公司在10月22日的纳斯达克听证会上提出的合规计划包括通过公开发行筹集800万美元,获得股东批准进行反向股票拆分,并在2024年12月16日之前完成一次要约收购,以将普通股换为非交易优先股。在截至2025年1月9日的延期期间,Elevai Labs必须及时通知纳斯达克任何影响其合规状态的重大事件。该公司必须在2024年11月22日之前请求纳斯达克上市和听证审查委员会对小组的决定进行审查,这将需要支付15,000美元的审查费用。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息